- Home
- PSNL vs KROS Comparison
PSNL vs KROS Comparison
Compare PSNL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | KROS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 584.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNL | KROS |
|---|---|---|
| Price | $6.68 | $10.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $12.20 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 2.1M | 248.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.58 | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | $69,648,000.00 | ★ $243,864,000.00 |
| Revenue This Year | $15.34 | N/A |
| Revenue Next Year | $41.46 | $2,751.79 |
| P/E Ratio | ★ N/A | $5.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.84 | $10.42 |
| 52 Week High | $11.50 | $22.55 |
Technical Indicators
Market Signals| Indicator | PSNL | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 37.42 |
| Support Level | $5.81 | N/A |
| Resistance Level | $7.04 | $15.97 |
| Average True Range (ATR) | 0.52 | 0.56 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 75.49 | 0.00 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.